{"id":93828,"date":"2023-08-28T08:18:12","date_gmt":"2023-08-28T06:18:12","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?post_type=ecosystem&p=93828"},"modified":"2023-08-28T08:18:14","modified_gmt":"2023-08-28T06:18:14","slug":"modiblast-pharma","status":"publish","type":"ecosystem","link":"https:\/\/cms.munich-startup.net\/en\/startups\/modiblast-pharma\/","title":{"rendered":"Modiblast Pharma"},"content":{"rendered":"

Modiblast Pharma is working to advance novel dendritic cell therapies for blood cancers into clinical development. The focus is on addressing the core problem of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS): the extremely high relapse rate after successful initial therapy.<\/p>\n

The Modiblast approach (3 patents granted) combines immunomodulators to stimulate blasts (cancer cells) to differentiate into leukemia-specific dendritic cells (DCleu) in the patient (in vivo). This induces both innate and adaptive immune cells in the blood and tissue to kill remaining or recurrent blasts and generate memory cells.<\/p>\n

Unlike CAR-T, for example, there is no need to identify and select specific target molecules. Furthermore, complicated and expensive ex vivo cell extraction and preparation procedures, as well as GMP facilities, are not required.<\/p>\n

Our long-term goal is to provide an easy-to-use, self-administered medication that can stabilize remissions or halt disease progression. This therapy can also normalize platelet\/neutrophil counts.<\/p>\n

The next step in clinical development is a phase 1a\/2b study, which recently passed the scientific advice of the BfArM.<\/p>\n<\/div>","protected":false},"featured_media":93829,"comment_status":"closed","ping_status":"closed","template":"","tags":[],"ecosystem_type":[2],"ecosystem_tag":[2707,2713],"acf":[],"yoast_head":"\nModiblast Pharma - Munich Startup<\/title>\n<meta name=\"description\" content=\"Modiblast Pharma arbeitet daran, mit neuartigen dendritischen Zelltherapien f\u00fcr Blutkrebserkrankungen in die klinische Entwicklungsphase einzutreten.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/startups\/modiblast-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Modiblast Pharma - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Modiblast Pharma arbeitet daran, mit neuartigen dendritischen Zelltherapien f\u00fcr Blutkrebserkrankungen in die klinische Entwicklungsphase einzutreten.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/startups\/modiblast-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-28T06:18:14+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/\",\"url\":\"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/\",\"name\":\"Modiblast Pharma - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg\",\"datePublished\":\"2023-08-28T06:18:12+00:00\",\"dateModified\":\"2023-08-28T06:18:14+00:00\",\"description\":\"Modiblast Pharma arbeitet daran, mit neuartigen dendritischen Zelltherapien f\u00fcr Blutkrebserkrankungen in die klinische Entwicklungsphase einzutreten.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg\",\"width\":2400,\"height\":639,\"caption\":\"Modiblast Pharma GmbH\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Modiblast Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"639\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Modiblast Pharma - Munich Startup","description":"Modiblast Pharma is working to advance novel dendritic cell therapies for blood cancers into clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/startups\/modiblast-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Modiblast Pharma - Munich Startup","og_description":"Modiblast Pharma arbeitet daran, mit neuartigen dendritischen Zelltherapien f\u00fcr Blutkrebserkrankungen in die klinische Entwicklungsphase einzutreten.","og_url":"https:\/\/cms.munich-startup.net\/en\/startups\/modiblast-pharma\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_modified_time":"2023-08-28T06:18:14+00:00","twitter_card":"summary_large_image","twitter_site":"@munich_startup","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/","url":"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/","name":"Modiblast Pharma - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg","datePublished":"2023-08-28T06:18:12+00:00","dateModified":"2023-08-28T06:18:14+00:00","description":"Modiblast Pharma is working to advance novel dendritic cell therapies for blood cancers into clinical development.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg","width":2400,"height":639,"caption":"Modiblast Pharma GmbH"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/startups\/modiblast-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Modiblast Pharma"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]},"og_image":[{"width":2400,"height":639,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2023\/08\/Modiblast-Pharma.jpeg","type":"image\/jpeg"}]},"_location_name":"","_location_street":"Buchenstr. 3","_location_zip":"82041","_location_city":"Oberhaching","_ecosystem_type":"startup","_foundingyear":"2020","_showyear":"1","_show_financing":"","_inactive":"","_founders":"8","_employees":"4","_businessmodel":"B2B","_stage":"Seed-Stage","_financing":"190.000\u20ac","_investors":"17","_investor_funding_rounds":"","_investor_details":"","_financing_history":"[{\"ecosystem_funding_round\":\"Seed\",\"ecosystem_funding_year\":\"2020\",\"ecosystem_funding_amount\":\"0 - 500.000 Euro\"},{\"ecosystem_funding_round\":\"Seed\",\"ecosystem_funding_year\":\"2021\",\"ecosystem_funding_amount\":\"0 - 500.000 Euro\"}]","_apple_appstore":"","_google_play":"","_user_email":"hns@modiblast.com","_user_password":"$2y$10$IUpnz\/aKwfFwy\/0e5aCjZurdmsPIREV3pESoPMnQSm0WzwyWHl4Ki","_description_en":"Modiblast Pharma is ready to advance into the clinical development phase with novel Dendritic Cell Therapies for liquid cancers. The focus is to target the core issue in acute myeloid leukemias (AML) and Myelodysplastic Syndromes (MDS): the extremely high rate of relapses after successful initial therapy.\r\n\r\nThe Modiblast approach (3 patents granted) combines immunomodulators to induce blast cells to differentiate into leukemia-specific dendritic cells (DCleu) in the patient. This triggers both innate and adaptive immune cells in blood and tissue to kill remaining or recurring blasts and generates memory cells.\r\n\r\nContrary to e.g. CAR-T there is no need to identify and select specific target molecules. And it doesn\u2019t require complicated and expensive ex vivo cell extraction and preparation procedures and GMP facilities.\r\n\r\nOur long-term goal is to provide an easy-to-use self-administered drug that can stabilize remissions or halt progression of the diseases. This therapy may also normalize thrombocyte\/neutrophil counts.\r\n\r\nThe next step of clinical development is a Phase 1a\/2b study which recently has passed BfArM scientific advice.","_founders_description":"","_founders_image":"","_logo_image":"","_contact":{"tel":"","hp":"https:\/\/www.modiblast.com","mail":"contact@modiblast.com","facebook":"","twitter":"","instagram":"","linkedin":"https:\/\/www.linkedin.com\/company\/modiblast"},"_thumbnail_id":"93829","_edit_lock":"1693203495:25","_edit_last":"25","_location_lat":"48.0144336","_location_long":"11.5882137","_wp_old_slug":"","wbounce_status":"default","_yoast_wpseo_primary_ecosystem_type":"2","_yoast_wpseo_primary_ecosystem_tag":"2707","_hide_on_map":"","_yoast_wpseo_content_score":"30","dealroom_id":"5005248","_dealroom_id":"field_5ea15c1318719","dealroom_json":"{\"error\":true,\"code\":429,\"message\":\"Too many calls\"}","_dealroom_json":"field_5ea15c251871a","dealroom_analytics_json":"{\"error\":true,\"code\":429,\"message\":\"Too many calls\"}","_dealroom_analytics_json":"field_5ea8354f2b0eb","_yoast_wpseo_focuskw":"Modiblast","_yoast_wpseo_metadesc":"Modiblast Pharma arbeitet daran, mit neuartigen dendritischen Zelltherapien f\u00fcr Blutkrebserkrankungen in die klinische Entwicklungsphase einzutreten.","_yoast_wpseo_linkdex":"58","_yoast_wpseo_estimated-reading-time-minutes":"1","_wp_old_date":"","_wp_desired_post_slug":"","_year":"","_yoast_wpseo_wordproof_timestamp":"","_yoast_wpseo_focuskw_text_input":"","_original_post_id":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem\/93828"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/ecosystem"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=93828"}],"version-history":[{"count":1,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem\/93828\/revisions"}],"predecessor-version":[{"id":93843,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem\/93828\/revisions\/93843"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/93829"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=93828"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=93828"},{"taxonomy":"ecosystem_type","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem_type?post=93828"},{"taxonomy":"ecosystem_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/ecosystem_tag?post=93828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}